Tepha Flexes Marketing Muscle

FDA today gave the thumbs up to Cambridge, MA-based Tepha, to market its TephaFLEX Absorbable Suture product in the U.S. TephaFLEX is the first device that the privately held firm developed from a new class of biopolymers derived from a recombinant DNA technology licensed from the Massachusetts Institute of Technology. Through a number of corporate partnerships already established by Tepha — including ones with Aesculap AG, HemCon Medical Technologies, LifeCell Corporation, NMT Medical and Tornier — this technology is being applied to a wide array of products such as sutures, surgical meshes for orthopedic and hernia repair, anti-adhesion films, hemostats, intra-cardiac devices, absorbable stents, ligament and tendon repair and replacement devices, embolization agents, and drug delivery systems. The TephaFLEX Absorbable Suture boasts up to 50% greater tensile strength than currently marketed monofilament absorbable sutures. In addition to high strength, the product offers surgeons improved flexibility, good knot security, and prolonged strength retention when implanted.  

The comments are closed.